Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and per…
$42.98-3.02%
报价 2026-11-06
市值
$2.04B
EV
$3.3B
PE (TTM)
12.4x
预期 PE (FY2027)
9.4x
52 周区间距高点 -38.8%
$42.98$70.21
筛选结果
pipeline · 2026-11-06Keep✗ 高增长✗ Cheap✓ GARP
GARP Pool: growth 10-30%, PE <= 20, EV/EBITDA <= 12, P/FCF <= 20, MC/GP <= 11
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22028-03 | 1.2x | 4.48 → 5.13（1.1x） | 8.4 |
| FY+32029-03 | 1.2x | 4.48 → 5.34（1.2x） | 8.0 |
毛利率 54% · TTM 收入 $1167M · 基数 EPS 4.48（调整后）
电话会信号
辅助标签Q2 20272026-11-05
下调/撤回指引供不应求
指引 下调
信心 3
分析师 3
“We expect to see the benefits from these acquisitions on long-term growth and value creation.”
原文引用（2）
- 下调/撤回指引：we are adjusting our fiscal 2027 outlook this morning to reflect production variability
- 供不应求：with zero safety stock, it has an outsized impact on near-term results
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| PBHPrestige Consumer Healthcare Inc. | $2.04B | -3.0% | +17.9% | 50% | 12.4x | 10.0x | 9.1x | GARP |
| CONConcentra Group Holdings Parent, Inc. | $5.38B | +0.2% | +9.0% | 31.7% | 22.9x | 14.2x | 13.0x | |
| LIVNLivaNova PLC | $4.96B | -1.3% | +10.4% | 67.4% | 25.1x | 22.4x | 38.4x | GARP |
| HTFLHeartflow, Inc. Common Stock | $4.56B | +0.9% | +43.4% | 83% | – | – | – | 高增长 |
| LEGNLegend Biotech Corporation | $4.33B | +3.8% | +39.4% | 55% | – | – | – | |
| ICUIICU Medical, Inc. | $4.3B | +2.7% | -0.8% | 36.4% | 90.1x | 20.0x | 52.4x | |
| PRVAPrivia Health Group, Inc. | $3.12B | +2.0% | +17.1% | 21% | 87.5x | 36.0x | 28.9x | |
| IRONDisc Medicine, Inc. | $3.03B | +0.6% | -47.5% | 0% | – | – | – | |
| ZLABZai Lab Limited | $2.87B | +12.7% | – | 56.5% | – | – | – | |
| 同行中位数 | – | – | +10.4% | 45.7% | 56.3x | 21.2x | 33.6x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-03-31 Q4 2026 | 2025-12-31 Q3 2026 | 2025-09-30 Q2 2026 | 2025-06-30 Q1 2026 | 2025-03-31 Q4 2025 | 2024-12-31 Q3 2025 | 2024-09-30 Q2 2025 | 2024-06-30 Q1 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $281.6M | $283.4M | $274.1M | $249.5M | $296.8M | $290.3M | $283.5M | $267.1M |
| Gross Margin | 50% | 55.5% | 56.2% | 54.2% | 59.2% | 55.5% | 55.5% | 54.7% |
| Operating Margin | 26.8% | 29.1% | 29.1% | 28.8% | 29.8% | 31.7% | 29.7% | 27% |
| Net Income | $53.9M | $46.7M | $42.2M | $47.5M | $50.1M | $61M | $54.4M | $49.1M |
| Diluted EPS | 1.13 | 0.97 | 0.86 | 0.95 | 1 | 1.22 | 1.09 | 0.98 |
| Operating Cash Flow | $50.6M | $78.3M | $57.5M | $79M | $61.8M | $65.1M | $69.8M | $54.8M |